When was Beren Therapeutics founded?

Beren Therapeutics was founded in 2020 and raised its 1st funding round 6 years after it was founded.

Where is Beren Therapeutics located?

Beren Therapeutics is headquartered in Bonn, Germany.

Is Beren Therapeutics a funded company?

Beren Therapeutics is a funded company, having raised a total of $135M across 2 funding rounds to date. The company's 1st funding round was a $***** Conventional Debt round, raised on Jun 10, 2026.

When was the latest funding round of Beren Therapeutics?

Beren Therapeutics' latest funding was a $***** Series D round on Jun 10, 2026, with participation from 5 investors. Its primary sector is Rare Diseases. In Germany, the Rare Diseases sector has seen $300M in funding in 2026 to date.

Where does Beren Therapeutics rank among its competitors?

Beren Therapeutics ranks 62nd amongst 278 active competitors, of which 78 are funded. It stands 5th in terms of total funding among its competitors. The most recent competitor to raise funding was Beren Therapeutics, which secured $165M in Jun, 2026.

Who are the top competitors of Beren Therapeutics?

Beren Therapeutics' top competitors include BridgeBio, Alnylam and PTC Therapeutics. Among them, Beren Therapeutics secured the most recent funding round in June, 2026.

Beren Therapeutics - 2026 Company Profile, Funding & Competitors

Beren Therapeutics is a series D company based in Bonn (Germany), founded in 2020. It operates as a Developer of therapeutics for genetic disorders and rare diseases. Beren Therapeutics has raised $135M in funding. The company has 278 active competitors, including 78 funded and 96 that have exited. Its top competitors include companies like BridgeBio, Alnylam and PTC Therapeutics.

Key Metrics

Founded Year

2020

Location

Bonn, Germany

Stage

Series D

Total Funding

$135M in 2 rounds

Latest Funding Round

Series D, Jun 10, 2026, $*****

Investors

Hercules Capital & 8 more

Ranked

62^nd among 278 active competitors

Similar Companies

BridgeBio & 312 more

View Beren Therapeutics' full profile

Beren Therapeutics has raised a total funding of $135M over 2 rounds. Its first funding round was on Jun 10, 2026. Its latest funding round was a Series D round on Jun 10, 2026 for $*****. 5 investors participated in its latest round. Beren Therapeutics has 9 institutional investors.

Here is the list of recent funding rounds of Beren Therapeutics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 10, 2026	2339066	Series D	3034514	3546313	1475445	8741896
Jun 10, 2026	1636670	Conventional Debt	4227980	9892858	3375368	Hercules Capital

Access funding benchmarks and valuations. Sign up today!

View details of Beren Therapeutics's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Beren Therapeutics include BridgeBio, Alnylam and PTC Therapeutics. Here is the list of Top 10 competitors of Beren Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	BridgeBio 2015, Palo Alto (United States), Public	Developer of therapeutics for the treatment of genetic diseases	$434M	Viking Global Investors, KKR & 20 others	81/100
2nd	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Atlas Venture & 13 others	79/100
3rd	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 28 others	77/100
4th	Alexion 1992, Zurich (Switzerland), Acquired	Developer of therapies for patients with devastating and rare diseases	$133M	Allen & Company, Invesco & 9 others	74/100
5th	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, T. Rowe Price & 6 others	73/100
6th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	71/100
7th	Bluebird Bio 1992, Cambridge (United States), Acquired	Developer of gene therapies for severe genetic and rare diseases	$136M	TVM Capital, Forbion & 10 others	71/100
8th	Agios Pharmaceuticals 2008, Cambridge (United States), Public	Developer of therapeutics in the field of cancer metabolism and rare genetic disorders of metabolism	$120M	Arch Venture Partners, Flagship Pioneering ... & 6 others	70/100
9th	Rhythm Pharmaceuticals 2010, Boston (United States), Public	Developer of peptide therapeutics for the treatment of rare genetic deficiencies	$84M	Pfizer Venture Investments, Third Rock Ventures ... & 8 others	70/100
10th	Generation Bio 2016, Cambridge (United States), Acquired	Developer of gene therapies for rare liver and eye diseases	$236M	T. Rowe Price, Fidelity Investments & 9 others	69/100
62nd	Beren Therapeutics 2020, Bonn (Germany), Series D	Developer of therapeutics for genetic disorders and rare diseases	$135M	Hercules Capital, Founders Fund & 7 others	54/100